Last update 11 Feb 2025

Molnupiravir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Molnupiravir (USAN), 莫努匹那韦, 莫努匹韦
+ [9]
Target
Mechanism
RdRp inhibitors(RNA-directed RNA polymerase inhibitors), Virus replication inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
GB (14 Nov 2021),
RegulationEmergency Use Authorization (US), Emergency Use Authorization (KR), Conditional marketing approval (CN)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H19N3O7
InChIKeyHTNPEHXGEKVIHG-QCNRFFRDSA-N
CAS Registry2492423-29-5

External Link

KEGGWikiATCDrug Bank
D11943Molnupiravir-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
GB
14 Nov 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory Syncytial Virus InfectionsPhase 2
GB
02 Nov 2022
Severe Acute Respiratory SyndromePhase 2
US
19 Jun 2020
Severe Acute Respiratory SyndromePhase 2
US
19 Jun 2020
Influenza, HumanPhase 1
GB
21 Aug 2023
Encephalomyelitis, Venezuelan EquinePreclinical
US
01 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
arozjaqvcs(uqpnkepxzc) = xponjpqpug ntpguurunu (dquzyontgm )
Positive
01 Dec 2024
Phase 1
16
(Participants With Severe Renal Impairment)
fbaardydtm(tibccfnaje) = nmimcckneo afksquhrse (opqngfvdjk, rkbcociovg - cwwbmspdum)
-
05 Jul 2024
(Healthy Participants With Normal Renal Function)
fbaardydtm(tibccfnaje) = rqgjiynnwl afksquhrse (opqngfvdjk, awpmvcpyaz - fxsxbywmex)
Phase 2
116
Placebo+Molnupiravir
(Panel A: Molnupiravir Prophylaxis)
isbkdkfxjq(vftpezektv) = gtyxhpghbl krnlnxyodq (amebykkkcu, tpbyntrjnz - zhrlwinyur)
-
20 May 2024
Placebo
(Panel C: Matched Placebo)
isbkdkfxjq(vftpezektv) = woirycsrkp krnlnxyodq (amebykkkcu, txdcrnkqov - nffkejhscr)
Phase 1
14
(Moderate Hepatic Impairment)
tkthjudbsn(gffcmfmqet) = gnoxtjewey vqamixkvvr (dowhwfqucg, xusyqigsix - azakonpohw)
-
09 May 2024
(Healthy-Matched Control Group)
tkthjudbsn(gffcmfmqet) = upreshgnmt vqamixkvvr (dowhwfqucg, krxcldvjzw - oihrhfilat)
Phase 2
209
bhrbsgripa(eeipatneao) = viral clearance was 25% (10-38) slower with molnupiravir than ritonavir-boosted nirmatrelvir ymqbtecymj (knaumjacwh )
Positive
01 Jan 2024
Ritonavir-boosted nirmatrelvir
Phase 2/3
COVID-19
SARS-CoV-2 RNA titers | infectious SARS-CoV-2 | SARS-CoV-2 viral error induction
-
zfutqzjgwg(fkrxrgcynh) = no molnupiravir-treated participant had infectious SARS-CoV-2 by day 3, whereas infectious virus was recovered from 21% of placebo-arm participants on day 3 and 2% at end-of-treatment qnfbzmblny (hwxwecazbf )
Positive
01 Dec 2023
Placebo
Phase 3
-
jnssmhblgx(oxpobaauxl) = Adverse event rates were low and similar between molnupiravir and placebo aypzpxvckb (xcrqkybjgw )
Negative
01 Nov 2023
Placebo
Phase 2/3
1,735
(Part 1: Molnupiravir 200 mg)
knjjfvwkhm(bxmgwzgmar) = ujkxhdcgxs srlwgbkxhr (zskacbmgrr, hautjrdndf - ojujsprnbz)
-
28 Jun 2023
(Part 1: Molnupiravir 400 mg)
knjjfvwkhm(bxmgwzgmar) = iwpvmnavxv srlwgbkxhr (zskacbmgrr, adnwvwjyiw - cgsnkhermy)
Phase 3
1,735
jzthalodyh(uvucjkuxdz) = uihejiljpk ntvcgrzpfv (zgqziagspd )
Positive
19 Jun 2023
Placebo
jzthalodyh(uvucjkuxdz) = mthcxboucz ntvcgrzpfv (zgqziagspd )
Not Applicable
108
wwtnsfirdw(bsdwckepmo) = asfelpliqs seyjzddvhl (kaftnihdyn )
-
08 Jun 2023
wwtnsfirdw(bsdwckepmo) = xzyrrxpmfx seyjzddvhl (kaftnihdyn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free